other material
confidence high
sentiment positive
materiality 0.75
Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials
Moleculin Biotech, Inc.
- Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.
- 65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.
- Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.
- Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.
- CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need.